Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2018-04-26 Interim / Quarterly Rep…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Appendix 4C - March 2018 quarter 6 pages 526.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C – March 2018 quarter' and is described as a quarterly report for entities subject to Listing Rule 4.7B. It contains detailed cash flow statements for the quarter ended March 2018, including operating, investing, and financing activities, as well as estimated cash outflows for the next quarter. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a comprehensive interim or quarterly financial report rather than an annual report or earnings release. The presence of detailed financial data and compliance statements confirms it is a formal quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-26 English
Chairman and CEO Address to Shareholders 3 pages 473.0KB
AGM Information Classification · 95% confidence The document contains the Chairman's and CEO's addresses delivered at the Annual General Meeting (AGM) of Telix Pharmaceuticals Limited. It includes welcome remarks, company updates, progress on clinical programs, and strategic outlook, all typical content for presentations or speeches at an AGM. There is no detailed financial data or comprehensive annual performance report, so it is not an Annual Report (10-K) or Interim Report (IR). The document is clearly tied to the AGM event and is not merely an announcement of a report publication. Therefore, the document fits the category of AGM Information (AGM-R). The document length (7812 characters) supports it being a substantive address rather than a brief announcement or certification.
2018-04-18 English
AGM - Results of Meeting 2 pages 208.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Telix Pharmaceuticals AGM Results of Meeting' and dated 19 April 2018. It reports the results of resolutions passed at the Annual General Meeting (AGM), including voting statistics for each resolution. The content focuses on the outcome of shareholder votes rather than the full AGM materials or presentations. The document length is 3406 characters, which is relatively short and consistent with a voting results announcement. The text references compliance with section 251AA of the Corporations Act, which pertains to disclosure of voting results. There is no detailed financial data, management discussion, or full report content. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-04-18 English
Translational Research Partnership with INSERM and ARRONAX 3 pages 169.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new translational research partnership between Telix Pharmaceuticals and research institutions INSERM and ARRONAX. It describes the nature of the collaboration, the research focus, and background information about the companies and institutions involved. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings or capital updates, and no mention of any report publication or certification. The content is primarily an announcement of a research partnership, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is moderate and contains detailed information about the partnership, but it is not a financial or governance report.
2018-04-15 English
Telix JV Entity Contract with Endocyte for Prostate Imaging 1
Regulatory Filings Classification · 95% confidence The document is a company announcement disclosing that a controlled entity of Telix Pharmaceuticals has entered into a material contract with Endocyte for prostate imaging technology. It references compliance with ASX Listing Rule 3.1, indicating a regulatory disclosure. The content focuses on the contract details and clinical trial information, not on financial results, management changes, or shareholder votes. The document length is relatively short (3064 characters) and does not contain financial statements or detailed financial data. It is an announcement of a material contract, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Capital/Financing Update or M&A Activity. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-04-09 English
Update - prostate imaging program 15 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is an update from Telix Pharmaceuticals on the progress of their prostate imaging program, including details about the Drug Master File (DMF) filed with the US FDA, regulatory steps, commercial implications, and clinical trial collaborations. It is presented as an investor update with detailed information on the technology, market opportunity, competition, and next steps. The document is not a formal financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. It is a detailed presentation aimed at investors and stakeholders about the company's progress and strategy regarding a specific product development program. Therefore, it fits best as an Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2018-03-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.